EMA Considers Accelerated Review Of Madrigal’s NASH Drug Filing, Discloses Other Fast-Track Decisions

 
• By Neena Brizmohun

Resmetirom, for noncirrhotic non-alcoholic steatohepatitis, is among the investigational products that the European Medicines Agency has been considering for review under its accelerated assessment pathway.

Calendar
The accelerated assessment mechanism can cut months off the standard review timeline • Source: Shutterstock

More from Europe

More from Geography